Besides anti-CXCL12 antibodies, the only molecule neutralizing all isoforms of CXCL12 is the L-RNA aptamer NOX-A12 [85], which is currently under evaluation in clinical trials as anticancer agent in chronic lymphoblastic leukemia, multiple myeloma, and metastatic colorectal and pancreatic cancer with liver metastasis (source: Clinicaltrials.gov). The gene discussed is CXCL12; the disease is plasma cell myeloma.